Diabetes Drug Market Research Report – Global Forecast to 2023

1. Market Research Future Diabetes Drug Market Diabetes Drug Market by Value, Revenue, Segments, Mega by Value, Revenue, Segments, Mega Trends Prominent Players and Outlook to 2023 Prominent Players and Outlook to 2023 Trends, , Global Diabetes Drugs Market - Scenario Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two type of diabetes namely type-1 diabetes and type-2 diabetes. During last decade there is a tremendous increase in the number of diabetic population. According to International Diabetes Federation, in 2016, it was estimated that 420 million adult population were suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040. A number of different types of drugs are available in the market however, no available treatment can cure diabetes totally. However, cost issues, strict regulatory rules and long approval time for drugs may led to restrain the growth of the market.The global Diabetes Drug Market is expected to grow at a CAGR of 9.2% during forecasted period 2017-2023. Request Sample copy at https://www.marketresearchfuture.com/sample_request/1160 Global Diabetes Drugs Market - Key Players The major player in the global diabetic drug market are Eli Lilly (US), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Biocon (US), Sunpharma (India), Sanofi (France), Novartis (Switzerland), Merck & Co. (US), Pfizer (US), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), Takeda (Japan). Global Diabetes Drugs Market - Segmentation The global diabetes drug market is segmented on the basis of types, route of administration, drug class, and end users. On the basis of types, the market is segmented into type-1 diabetes and type-2 diabetes. On the basis of route of administration, the market is segmented into oral, intravenous and other. On the basis of drug class they are insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, secretagogues, peptide analogs and others. Sensitizers are sub segmented into thiazolidinediones and biguanides. Secretagogues are further segmented into sulfonylureas and non-sulfonylureas On the basis of end users, the market is segmented into hospital & clinics, ambulatory clinics and other. Regional Wise Analysis:

2. Market Research Future America dominates the global diabetes drug market owing to large diabetic patient population. According to the WHO, in 2016, 9.6% of total America population were suffering from diabetes. In addition to this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. Increasing cholesterol level and smoking increases the possibility of causing diabetes. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US had diagnosed with high cholesterol level. Europe accounts for the second largest diabetes drug market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market in Europe. Browse Complete Report athttps://www.marketresearchfuture.com/reports/diabetes-drug-market- 1160 About US: Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. Contact Us: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, India Phone: +1 646 845 9312 Email: sales@marketresearchfuture.com